Volume 14, Issue 4, Pages 306-316 (April 2013) Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)  Dr Ruth E Langley, MRCP, Fay H Cafferty, PhD, Abdulla A Alhasso, FRCR, Stuart D Rosen, MD, Subramanian Kanaga Sundaram, FRCS, Suzanne C Freeman, MSc, Philip Pollock, MRes, Rachel C Jinks, PhD, Ian F Godsland, PhD, Roger Kockelbergh, FRCS(Urol), Prof Noel W Clarke, ChM, Prof Howard G Kynaston, FRCS (Urol), Prof Mahesh KB Parmar, DPhil, Prof Paul D Abel, ChM  The Lancet Oncology  Volume 14, Issue 4, Pages 306-316 (April 2013) DOI: 10.1016/S1470-2045(13)70025-1 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Randomisation was 2:1 (oestrogen patches:LHRHa). LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches. *One patient did not start treatment, withdrew soon after randomisation, and did not attend any trial visits. †Men with oestradiol concentraions of 250 pmol/L or lower were assumed not to be using OP and were excluded. ‡Includes a small number of individuals (maximum 3) who had been assumed not to be receiving treatment at an earlier time (eg, owing to low oestradiol concentrations, reported difficulty in using OP, or missed appointments). The Lancet Oncology 2013 14, 306-316DOI: (10.1016/S1470-2045(13)70025-1) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Changes in fasting glucose (A) and total cholesterol (B) concentrations in patients still receiving treatment at 6 and 12 months Patients were not receiving additional therapy. Boxes indicate median and IQR, whiskers indicate 1·5×IQR, and dots indicate outlying values. LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches. The Lancet Oncology 2013 14, 306-316DOI: (10.1016/S1470-2045(13)70025-1) Copyright © 2013 Elsevier Ltd Terms and Conditions